GridAI Technologies (GRDX)

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

The GridAI Technologies Corp. Common Stock (GRDX) stock price today is $2.31, reflecting a -4.15% move since the market opened. The company’s market capitalization stands at $7.77M, with a daily trading volume of $226.83K shares. For investors tracking price trends, GridAI Technologies Corp. Common Stock stock has ranged between $2.31 and $2.53 today. The previous closing price was $2.41.

Ready to get started? Follow the steps below, or read our guide on how to buy GridAI Technologies stock on Kraken starting from $10.